Global Cell and Gene Therapy CDMO Services Market Strategic Research Report

The global cell and gene therapy contract development and manufacturing organization (CDMO) services market stood at approximately USD 4.8 billion in 2024 and is on a trajectory that reflects the structural transformation underway in advanced therapeutics manufacturing. As pharmaceutical and biotechnology sponsors increasingly outsource the technically demanding production of autologous and allogeneic cell therapies, viral vectors, and gene-editing constructs, specialized CDMOs have become indispensable partners in translating clinical breakthroughs into commercially viable treatments. The sector's significance extends beyond contract manufacturing economics: it represents a critical bottleneck — and therefore a critical opportunity — in the broader advanced therapy medicinal product (ATMP) value chain, where manufacturing constraints have historically been the primary obstacle between promising trial data and patient access.

Three interlocking forces are propelling market expansion toward an estimated USD 13.1 billion by 2032. First, the accelerating clinical pipeline of cell and gene therapies — with over 3,500 active trials globally as of 2024 — is generating unprecedented demand for GMP-compliant process development and scale-up services that most sponsors lack the internal capacity to provide. Second, the increasing approval velocity of ATMPs by the U.S. FDA and EMA, including CAR-T cell therapies and AAV-based gene therapies, is converting development-stage CDMO contracts into multi-year commercial manufacturing agreements that carry substantially higher revenue per engagement. Third, the shift toward allogeneic, off-the-shelf cell therapy platforms is driving CDMOs to invest in large-scale bioreactor infrastructure, automation, and cryopreservation logistics, creating differentiated service tiers with meaningful pricing power. Against these tailwinds, the market faces a persistent constraint in the form of specialized workforce shortages, particularly bioprocess engineers and quality assurance personnel with ATMP-specific experience, which lengthens facility ramp-up timelines and constrains capacity expansion at established CDMOs.

This report delivers a comprehensive quantitative and qualitative analysis of the global cell and gene therapy CDMO services market across the 2025–2032 forecast period, with historical context from 2019 through 2024. Coverage spans service type, therapy modality, end-use client segment, and regional geography, with granular country-level forecasts for the six most strategically important markets. Corporate strategy teams evaluating build-versus-buy decisions, investment analysts assessing CDMO platform valuations, M&A advisors tracking consolidation activity, and procurement managers benchmarking supplier capabilities will each find actionable intelligence calibrated to their specific decision contexts.